Home › Osteosarcoma › North Carolina
Pag-aaral pangklinika para sa Osteosarcoma sa North Carolina
6 pag-aaral para sa Osteosarcoma ang naghahanap ng mga kalahok sa mga site sa North Carolina.
Mga Lungsod sa North Carolina
Opisyal na teksto ng pag-aaral (English)
Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
- Duke University Medical Center, Durham
Nagre-recruitPhase 2
Edad 12 hanggang 39 · Lahat ng kasarian · Na-update Set 29, 2026 · NCT04616560The CATSINDO Trial - Clinical and Translational Study in Newly Diagnosed Osteosarcoma
- University of North Carolina at Chapel Hill, Chapel Hill
- Atrium Health Levine Children's Hospital, Charlotte
- Novant Health Hemby Children's Hospital, Charlotte
- at 3 pa
Nagre-recruitPhase 2
Edad 7 hanggang 22 · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07560826Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
- Mission Hospital, Asheville
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Duke University Medical Center, Durham
- at 2 pa
Nagre-recruitPhase 3
Hanggang edad 50 · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT05235165SPEARHEAD-3 Pediatric Study
- Duke University School of Medicine, Durham
Nagre-recruitPhase 1/2
Edad 2 hanggang 21 · Lahat ng kasarian · Na-update Ago 11, 2026 · NCT05642455Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Mission Hospital, Asheville
- Wake Forest University Health Sciences, Winston-Salem
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update May 18, 2026 · NCT01790152Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
Nagre-recruitPhase 1
18 Months · Lahat ng kasarian · Na-update Mar 27, 2026 · NCT03721068Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.